Sanofi turns to G-BA for Jevtana benefits decision after vague IQWiG's assessment
This article was originally published in Scrip
Executive Summary
Sanofi'sJevtana (cabazitaxel) could offer considerable additional benefit for castration-resistant prostate cancer patients aged 65 and over who are unable to continue with docetaxel (Sanofi's Taxotere), says IQWiG, the German HTA institute. Meanwhile, for patients under 65 there is just a "hint" of unquantifiable benefit. The assessment is vague and leaves too much scope for interpretation, says EUCOPE, the European Confederation of Pharmaceutical Entrepreneurs.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.